Shots:
- The P-III study assessing safety & efficacy of HLX11 vs Perjeta (pertuzumab) in addition to trastuzumab & docetaxel (Q3W, 4 cycles) as a neoadjuvant regimen for treating patients, randomized 1:1, with HER2+/HR- locally advanced breast cancer has reached the 1EP
- The 1EP of the trial includes total pathological complete response (tpCR) rate as per IRC while the 2EPs are tpCR rate assessed by investigators, breast pathologic complete response (bpCR) rate, ORR, EFS, DFS, safety, PK & immunogenicity
- Additionally, Henlius granted Organon exclusive global commercialization rights (excl. China) for two biosimilar candidates, incl. HLX11, as per a license and supply agreement signed in 2022
Ref: Organon and Shanghai Henlius | Image: Organon and Shanghai Henlius| Press Release
Related News:- Formycon and Fresenius Kabi Reports the EC’s Approval of Otulfi (Biosimilar, Stelara) for Serious Inflammatory Diseases
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
